uuxn:T332P5AD-ADDE-455D-9523-133DF215D32A
TCGA-—YL-A85K-e1A-PR Redailted

IIIIIIIIIIIIIIIIIII
IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII|I|II||IIllIIlI

PROSTATE AND LYMPH NODES: RADICAL PROSTATECTOMY:

TUMOR PROCUREMENT:

HISTOLOGIC TYPE
ACINAR ADENOCARCINOMA

HISTOLOGIC GRADE (PRIMARY PATTERN+SECONDARY PATTERN = GLEASON SCORE):
4 + 5 = 9

TERTIARY PATTERN NOT PRESENT 6W = 5’ “I PW
PERCENTAGE OF DIFFERENT GLEASON PATTERNS , dag «
NOT DETERMINED d" E“ ‘" I I3
TUMOR LOCATION
APEX
MID
BASE
BLADDER NECK
ANTERIOR
R'GHT TA’AD {D 23
LEFI‘ I“ , _ 1
POFEEIET'OR AAQJLZ‘M’I—éﬂwﬁvwﬁ) NOB 3/40/13
I“
LEFI' ,; . K . E .
EXTRA-PROSTATIC EXTENSION EXACT; (97%wa NOS; (ICC/.6]
PRESENT -- ~
NON-FOCAL , \‘u (1
SITE OF EXTRA-PROSTATIC EXTENSION $47” //52 ‘42)} 7’

NOT REPORTED
SEMINAL VESICAL INVASION
PRESENT
BOTH ,
SURGICAL MARGINS
INVOLVED BY INVASIVE CARCINOMA
APEX
BLADDER NECK
ANTERIOR
RIGHT
LEFT
POSTERIOR
RIGHT
LEFI'
NATURE OF POSITIVE MARGINS
NOT REPORTED
EXTENT OF POSITIVE MARGINS
MULTIFOCAL
MILLIMETRIC EXTENT OF POSITIVE MARGINS: NOT REPORTED
GLEASON GRADE OF CARCINOMA PRESENT AT THE POSITIVE MARGINS
NOT REPORTED
LYMPHOVASCULAR INVASION
PRESENT
PERINEURAL INVASION
PRESENT
TUMOR VOLUME
PROPORTION OF PROSTATE INVOLVED BY CARCINOMA: _60%
TREATMENT EFFECT ON CARCINOMA ‘
NOT APPLICABLE
LYMPH NODES

Initials

 

RIGHT OBTURATOR

NUMBER OF NODES INDENTIFIED: _2_

NUMBER OF NODES INVOLVED BY METASTASIS: _0_
LEFT OBTURATOR

NUMBER OF NODES IDENTIFIED: _7_

NUMBER OF NODES INVOLVED BY METASTASIS: _0_
RIGHT EXTERNAL ILIAC

NUMBER OF NODES IDENTIFIED: _4_

NUMBER OF NODES INVOLVED BY METASTASIS: _4_
LEFT EXTERNAL ILIAC

NUMBER OF NODES IDENTIFIED: _3__

NUMBER OF NODES INVOLVED BY MET ASTASIS: _0_
RIGHT INTERNAL ILIAC

NUMBER OF NODES IDENTIFIED: _4_

NUMBER OF NODES INVOLVED BY METASTASIS: _0_

ADDITIONAL PATHOLOGIC FINDINGS
HIGH-GRADE PROSTATIC INTRA-EPITHELIAL NEOPLASIA
NODULAR HYPERPLASIA
PATHOLOGICAL STAGING

pT3b
pN1
pMX

 

 

 

 

TCGA Pathologic Diagnosis Discrepancy Form

 

 

 

 

 

 

lehuﬂ source bite Li SS}: _

mm The TCGA Pathologic Diagnosis Discrepancy Form should be completed when the pathologic diagnosis
documented on the initial pathology report for a case submitted for TC GA is inconsistent with the diagnosis provided on the

 

_‘l'b‘s Identiﬁer:

TSS Unique Patient Identiﬁer:

 

 

 

 

 

 

 

 

 

Com leted I3 (Interviewor Name on OpenCiim‘ca): V _Com leted Date: ;
Y
Diagnosis Information
ii Data Element Entry Alternatives Working Instructions
Provide the diagnosis] histologic suhtypeL'.) documented on
Pathologic Diagnosis ‘~ » . .. ‘3 the initial pathology report for this case. lithe histology for
1 Provided an Initial 0W” ”’4. this case is mixed, provide all listed subtypes.
Pathology Report Git—Ili‘tD/d 4+5; 7
H' I I v. f I f Provide the histologic features selected on the TCGA Case
“1': :aombgfe :10::Z:3 /} (ﬂu I ()CﬁWC/ , LIA/7‘ Quality Control Point completed for this case.
2 M f m
for TCGA as reﬂected m .I i p _
' , J i :2 1‘ —
on the CQCF. Li‘- 4 9
Discrepancy between Pathology Report and Case Quality Control Form
3 Provide the reason for I’rolviclle a reason triescli'fbing wlhy the diaglnosis on tgiehmiliai
. . pat ID ogy report or is case 5 not cons stem wit i e
{iléitglesitgietgfgjlhology pail ;, ail) SQUI’LE AY/JLUCQ) diagnosis selected on the ’I'CGA Case Quality Control Form.
report and the TCGA
Case Quality Control ‘, ,
Form. H010; Pry/(31A; 5 (Vi/bu ,1
[Wit-2w iﬁ'SLbc’“)
Name of'l‘SS Reviewing Fronds the name of the pathologist who reviewed this case
4 Pathologist or or x ' A‘
Biorepository Director

 

 

 

 

 

I acknowledge that the above Information provided by my institution Is true and Correct and has been quality con trolled.

 

TSS Reviewing Pathologist Or Biorepository Director

J acknowledge that the above information provided by my institution is true and correct and has been quality controlled The Attending Pathologist or the
Department Chairman has been informed or is aware of the above discrepancy in diagnoses.

Principal Investigator Signature

 

Date

 

 

